F10 and COVID-19: In this observational study, the peak anti-FXa levels are described in critically ill non-COVID-19 and COVID-19 patients treated with the registered nadroparin prophylactic dosage of 2850 IU OD sc and increased dosages of 5700 IU OD sc or BID sc in accordance with the then current Dutch guidelines for anticoagulation in COVID-19.